Nomura Asset Management Co. Ltd. Cuts Stock Holdings in Becton, Dickinson and Company $BDX

Nomura Asset Management Co. Ltd. reduced its holdings in Becton, Dickinson and Company (NYSE:BDX) by 2.7% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 581,016 shares of the medical instruments supplier’s stock after selling 16,108 shares during the period. Nomura Asset Management Co. Ltd.’s holdings in Becton, Dickinson and Company were worth $112,758,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in BDX. Wellington Management Group LLP grew its stake in shares of Becton, Dickinson and Company by 9,056.3% in the 3rd quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier’s stock worth $979,290,000 after buying an additional 5,174,944 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Becton, Dickinson and Company by 13.0% in the 4th quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier’s stock worth $7,118,282,000 after buying an additional 4,223,149 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its stake in shares of Becton, Dickinson and Company by 23,219.2% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 4,155,709 shares of the medical instruments supplier’s stock worth $769,397,000 after buying an additional 4,137,888 shares in the last quarter. Norges Bank bought a new position in shares of Becton, Dickinson and Company during the 4th quarter valued at approximately $734,321,000. Finally, First Eagle Investment Management LLC increased its position in shares of Becton, Dickinson and Company by 16.5% during the 4th quarter. First Eagle Investment Management LLC now owns 11,646,000 shares of the medical instruments supplier’s stock valued at $2,260,139,000 after purchasing an additional 1,651,592 shares during the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

BDX has been the topic of several recent research reports. Stifel Nicolaus decreased their price target on Becton, Dickinson and Company from $215.00 to $175.00 in a report on Thursday, May 7th. Zacks Research upgraded shares of Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a report on Friday, April 10th. Piper Sandler lowered their target price on shares of Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating for the company in a report on Friday, April 17th. JPMorgan Chase & Co. lowered their target price on shares of Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating for the company in a report on Tuesday, February 10th. Finally, Royal Bank Of Canada set a $175.00 target price on shares of Becton, Dickinson and Company in a report on Tuesday, April 14th. Seven equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $183.64.

Becton, Dickinson and Company Trading Down 0.9%

NYSE BDX opened at $147.13 on Friday. The company has a quick ratio of 0.55, a current ratio of 0.94 and a debt-to-equity ratio of 0.62. The firm has a market cap of $40.54 billion, a PE ratio of 37.25, a price-to-earnings-growth ratio of 10.42 and a beta of 0.22. The company has a 50 day moving average price of $151.63 and a 200 day moving average price of $177.02. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, topping the consensus estimate of $2.77 by $0.13. The firm had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.67 billion. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. Becton, Dickinson and Company’s revenue was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.35 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. As a group, sell-side analysts forecast that Becton, Dickinson and Company will post 12.61 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th will be paid a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a dividend yield of 2.9%. The ex-dividend date is Tuesday, June 9th. Becton, Dickinson and Company’s payout ratio is 106.33%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.